
|Articles|March 1, 2007
B&L invests in presbyopia
Bausch & Lomb has made an equity investment in AcuFocus.
Advertisement
Bausch & Lomb has made an equity investment in - and secures an exclusive option to purchase - AcuFocus, a privately held company in California, USA.
AcuFocus is developing a corneal inlay, the ACI 7000, for the treatment of presbyopia. The inlay is implanted in the cornea under a LASIK flap and incorporates technology that increases a patient's depth of field, thereby improving near vision. The procedure involves no tissue removal and does not permanently alter the cornea, so pre-implant vision can be restored should the inlay be removed. Terms of the agreement were not disclosed.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
BL1332 misses primary end point in phase 2 post-PRK ocular pain study
2
FLORetina-ICOOR 2026: AI moves from the image to the trial, the clinic, and the operating room
3
Water-soluble CBD eye drops lower IOP and dampen corneal sensitivity in glaucoma mouse model
4
Q&A: GLP-1 RAs and NAION, the case for a baseline exam
5











